Drug Trial Radar · NCT07770217
A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Aug 2, 2026
Primary completion
Sep 10, 2026
Study completion Nov 29, 2026
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, fixed-sequence, self-controlled Phase I clinical study with a planned enrollment of approximately 18 healthy participants.
Conditions
- Healthy Participants
Interventions
HS-10504Drug
Participants will receive a single oral dose of 400 mg HS-10504 tablets on study days D1 and D17, respectively
RifampinDrug
articipants will receive Rifampin capsules 600 mg orally once daily on an empty stomach from Day 10 to Day 24 for 15 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of CmaxTime frame: 192 hours after administration of HS-10504
- Evaluation of AUC0-tTime frame: 192 hours after administration of HS-10504
- Evaluation of AUC0-∞Time frame: 192 hours after administration of HS-10504
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.